What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary scientific interests are in Surgery, Internal medicine, Ovarian cancer, Oncology and Chemotherapy.
In Surgery, Ignace Vergote works on issues like Placebo, which are connected to Maintenance therapy and Phases of clinical research.
In his work, Adjuvant is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine.
The study incorporates disciplines such as Survival analysis, Cancer research and Serous fluid in addition to Ovarian cancer.
His Oncology research integrates issues from Ovarian carcinoma, Pathology, Breast cancer and Anastrozole.
In general Chemotherapy, his work in Performance status and Doxorubicin is often linked to In patient linking many areas of study.
His most cited work include:
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study (741 citations)
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (640 citations)
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG (583 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Ovarian cancer, Surgery and Chemotherapy are his primary areas of study.
His work on Cancer, Breast cancer and Carboplatin as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines.
His Carboplatin study frequently draws connections between related disciplines such as Regimen.
His research in Oncology tackles topics such as Stage which are related to areas like Cervical cancer.
His Ovarian cancer research incorporates themes from Cancer research, Serous fluid and Bioinformatics.
His work on Surgery is being expanded to include thematically relevant topics such as Clinical trial.
He most often published in these fields:
- Internal medicine (54.04%)
- Oncology (43.82%)
- Ovarian cancer (35.15%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (54.04%)
- Oncology (43.82%)
- Ovarian cancer (35.15%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Cancer research.
His Internal medicine study frequently links to related topics such as Gastroenterology.
The concepts of his Oncology study are interwoven with issues in Carboplatin, Bevacizumab and Stage.
His research in Stage focuses on subjects like Cervical cancer, which are connected to Surgery and Lymph node.
His research investigates the connection between Ovarian cancer and topics such as Quality of life that intersect with problems in Concomitant.
His Chemotherapy research is multidisciplinary, incorporating elements of Ovarian carcinoma, Tolerability and Cohort.
Between 2016 and 2021, his most popular works were:
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (640 citations)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (138 citations)
- Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening (84 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Ignace Vergote focuses on Internal medicine, Ovarian cancer, Chemotherapy, Oncology and Cancer research.
His Ovarian cancer research is multidisciplinary, incorporating perspectives in Maintenance therapy, Immune system and Disease.
His research in Chemotherapy intersects with topics in Ovarian carcinoma, Debulking, Binimetinib and Fallopian tube.
His research integrates issues of Cancer, Tolerability, Recurrent Ovarian Cancer and Antibody-drug conjugate in his study of Oncology.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Cell and Epithelial ovarian cancer.
His Randomized controlled trial study is focused on Surgery in general.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
